Drug Trial Radar · NCT04742907
Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection
Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
402
Actual
Start
Jul 29, 2021
Primary completion
Mar 25, 2024
Study completion May 1, 2024
Sponsor
- Lead sponsor
- Tsumura USAIndustry
- Sponsor type
- Industry
- First posted
- Feb 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of postoperative ileus (POI) in subjects undergoing open or laparoscopic bowel resection (BR).
Conditions
- Enhanced Recovery After Surgery
Interventions
TU-100Drug
Treatment with investigational product
PlaceboDrug
Treatment with placebo product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Gastrointestinal Recovery (GIR)Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Florence Site
Florence, Alabama
Gilbert Site
Gilbert, Arizona
Little Rock Site
Little Rock, Arkansas
Duarte Site
Duarte, California
Los Angeles Site #1
Los Angeles, California
Los Angeles Site #2
Los Angeles, California
Palo Alto Site
Palo Alto, California
Sacramento Site
Sacramento, California
Danbury Site
Danbury, Connecticut
Clearwater Site
Clearwater, Florida
Orlando Site
Orlando, Florida
Tampa Site
Tampa, Florida
Weston Site
Weston, Florida
Chicago Site #2
Chicago, Illinois
Chicago Site #1
Chicago, Illinois
Urbana Site
Urbana, Illinois
Lexington Site
Lexington, Kentucky
Metairie Site
Metairie, Louisiana
Boston Site #1
Boston, Massachusetts
Detroit Site
Detroit, Michigan
St. Louis Site
St Louis, Missouri
Newark Site
Newark, New Jersey
Mineola Site
Mineola, New York
New York Site
New York, New York
Stony Brook Site
Stony Brook, New York
Cleveland Site #2
Cleveland, Ohio
Cleveland Site #1
Cleveland, Ohio
Philadelphia Site #2
Philadelphia, Pennsylvania
Pittsburgh Site
Pittsburgh, Pennsylvania
Charleston Site
Charleston, South Carolina
Memphis Site
Memphis, Tennessee
Dallas Site
Dallas, Texas
Fort Worth Site
Fort Worth, Texas
Salt Lake City Site
Salt Lake City, Utah
Roanoke Site
Roanoke, Virginia
Milwaukee Site
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.